NCT04874194 2025-11-03
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
Phase 1/2 Terminated
M.D. Anderson Cancer Center
University of Illinois at Chicago
Emory University
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Roswell Park Cancer Institute